Sponsor Check › Samara Innovations › Issuer
Corporation · organized in DELAWARE · formed Over five years ago · NEW HAVEN, CT · SEC CIK 1865257
Part of sponsor group: Samara Innovations (12 issuers, 33 filings) · grouped because: shared people · confidence 78% · Not the same sponsor? Request a correction
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 21, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. State securities regulator actions: not yet searched. · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:14 PM ET.
0 of 4 offerings report sales commissions; 1 reports finder's fees totalling $328,671; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 2, 2021 D File 021-401376 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and directors. | None listed |
| EDGAR ↗ | Feb 10, 2023 D File 021-473164 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and directors. | None listed |
| EDGAR ↗ | Mar 3, 2026 D File 021-575214 | $0 | $0 | $0 No amount other than ordinary course employment compensation is being paid to officers and directors. | None listed |
| EDGAR ↗ | Oct 21, 2026 D/A File 021-583522 | $0 | $328,671 | $0 No amount other than ordinary course employment compensation is being paid to
officers and directors. | Supervision Partners LLC BrokerCheck CRD 300528 ↗ |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D/A (amendment) filed Oct 21, 2026 · amends 0001865257-26-000004 ↗ SEC file no. 021-583522 · accession 0001865257-26-000005 |
|---|---|
| Raise progress | $27,927,729 sold of $29,999,999 offered (93%) · $2,072,270 remaining |
| Filing timing | Date of first sale: May 4, 2026 · Form D filed: Oct 21, 2026 (170 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 173 days (0.5 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 33 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | Supervision Partners LLC — FINRA BrokerCheck CRD 300528 ↗ Solicits in: AL, CA, CO, CT, DE, FL, GA, HI, IL, IA, KY, ME, MA, MI, MN, MO, NV, NH, NJ, NY, NC, OH, OK, PA, RI, SC, TN, TX, UT, VA, WA, WI |
| Money to insiders | Sales commissions: $0 · Finder's fees: $328,671 · Proceeds to officers, directors, promoters: $0 No amount other than ordinary course employment compensation is being paid to
officers and directors. |
| Signed by | Dr. Stephen Bloch, Chief Executive Officer (Oct 21, 2026) |
| Changes vs prior filing | total sold: $26,427,730 → $27,927,729 investors: 32 → 33 finder's fees: $149,358 → $328,671 Compared with the D filed May 11, 2026 (EDGAR ↗). Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $29,999,999. Typical range: $2,000,000–$19,999,994. Investors: 33. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed May 11, 2026 SEC file no. 021-583522 · accession 0001865257-26-000004 |
|---|---|
| Raise progress | $26,427,730 sold of $29,999,999 offered (88%) · $3,572,269 remaining |
| Filing timing | Date of first sale: May 4, 2026 · Form D filed: May 11, 2026 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 173 days (0.5 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 32 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | Supervision Partners LLC — FINRA BrokerCheck CRD 300528 ↗ Solicits in: AL, CA, CO, CT, DE, FL, GA, HI, IA, IL, KY, MA, ME, MI, MN, MO, NC, NH, NJ, NV, NY, OH, OK, PA, RI, SC, TN, TX, UT, VA, WA, WI |
| Money to insiders | Sales commissions: $0 · Finder's fees: $149,358 · Proceeds to officers, directors, promoters: $0 No amount other than ordinary course employment compensation is being paid to officers and directors. |
| Signed by | Dr. Stephen Bloch, Chief Executive Officer (May 11, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $29,999,999. Typical range: $2,000,000–$19,999,994. Investors: 32. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Mar 3, 2026 SEC file no. 021-575214 · accession 0001865257-26-000003 |
|---|---|
| Raise progress | $3,324,918 sold of $4,000,000 offered (83%) · $675,082 remaining |
| Filing timing | Date of first sale: Feb 23, 2026 · Form D filed: Mar 3, 2026 (8 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 243 days (0.7 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 12 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Option, warrant or other right to acquire; Other: Simple Agreements for Future Equity (SAFEs) |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 No amount other than ordinary course employment compensation is being paid to officers and directors. |
| Signed by | Dr. Stephen Bloch, Chief Executive Officer (Mar 3, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $4,000,000. Typical range: $2,000,000–$19,999,994. Investors: 12. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 10, 2023 SEC file no. 021-473164 · accession 0001865257-23-000001 |
|---|---|
| Raise progress | $2,308,569 sold of $2,308,569 offered (100%) · $0 remaining |
| Filing timing | Date of first sale: Feb 3, 2023 · Form D filed: Feb 10, 2023 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,359 days (3.7 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 11 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 No amounts other than ordinary course employment compensation is being paid to officers and directors. |
| Signed by | Dr. Stephen Bloch, Chief Executive Officer (Feb 9, 2023) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $2,308,569. Typical range: $2,000,000–$19,999,994. Investors: 11. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jun 2, 2021 SEC file no. 021-401376 · accession 0001865257-21-000001 |
|---|---|
| Raise progress | $7,581,493 sold of $8,031,491 offered (94%) · $449,998 remaining |
| Filing timing | Date of first sale: May 26, 2021 · Form D filed: Jun 2, 2021 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,977 days (5.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 10 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 No amounts other than ordinary course employment compensation is being paid to officers and directors. |
| Signed by | Dr. Stephen Bloch, Chief Executive Officer (Jun 1, 2021) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $8,031,491. Typical range: $2,000,000–$19,999,994. Investors: 10. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 2 new offerings in the last 12 months · most recent filing Oct 21, 2026.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| Gregory P Ho | Director | NY | Mar 3, 2026 → Oct 21, 2026 | — |
| Kevin L. Rakin | Director | CT | May 11, 2026 → Oct 21, 2026 | 7 other issuers |
| Paul Fonteyne | Director | CT | Mar 3, 2026 → Oct 21, 2026 | — |
| Robert A Bettigole | Director | CT | Mar 3, 2026 → Oct 21, 2026 | 4 other issuers |
| Stephen Bloch | Executive Officer, Director | CT | Jun 2, 2021 → Oct 21, 2026 | 8 other issuers |
| Stephen Strittmatter | Director | CT | Jun 2, 2021 → Oct 21, 2026 | 1 other issuer |
| Timothy Siegert | Executive Officer | CT | Oct 21, 2026 | — |
| Timothy A Siegert | Executive Officer | CT | Mar 3, 2026 → May 11, 2026 | — |
| Jennifer A Gabler | Executive Officer | CT | Mar 3, 2026 | — |
| Gregory P. Ho | Director | NY | Jun 2, 2021 → Feb 10, 2023 | 17 other issuers |
| Paul P. Fonteyne | Director | CT | Jun 2, 2021 → Feb 10, 2023 | 3 other issuers |
| Robert A. Bettigole | Director | CT | Jun 2, 2021 → Feb 10, 2023 | 4 other issuers |
| Timothy P. Siegert | Executive Officer | CT | Jun 2, 2021 → Feb 10, 2023 | — |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people:
Shared address: this business address appears on filings for 1 other issuer. Stated as a count only — many addresses are shared office buildings or registered agents.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for Allyx Therapeutics, Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.